A Hong Kong IPO will make one of the world’s richest biopharma families

fiercepharma | June 13, 2019

China’s Hansoh Pharmaceutical is slated to go public in Hong Kong on Friday. The HK$7.86 billion ($1 billion) raise puts it among the largest IPOs on the exchange this year. But perhaps what’s more interesting is how the market value will create one of the world’s wealthiest biopharma families. The IPO values Hansoh at $10.4 billion, and with a 68% stake, its founder, chairwoman and CEO, Zhong Huijuan, will be worth $7.9 billion, according to Bloomberg. But her husband’s company, Jiangsu Hengrui Medicine, is perhaps better known in the Western world. The Shanghai-listed anticancer drugmaker has given Zhong’s husband Sun Piaoyang, who holds about one-fourth of equity interest, a $9.3 billion stake. Combined, they sit among the world’s richest biopharma families, beating out the Sacklers of Purdue Pharma, whose fortune in 2016 totaled around $14 billion by Forbes’ estimate before their opioid fallout. Both Hansoh and Hengrui have benefited from China’s fast-growing drug industry. Healthcare expenditure in China increased to 5.87 trillion yuan in 2018 ($848 billion) from 3.53 trillion yuan ($510 billion) in 2014, and it's expected to reach 9.35 trillion yuan ($1.35 trillion) in 2023, Hansoh said in its prospectus, citing data from the Chinese government.

Spotlight

The role that nanoparticles play in the rapidly developing field of ‘NanoMedicine’ has been discussed previously in Chapter 5. In this Chapter, we review the specificmechanisms by which such nanoparticles are designed and formulated and in which NTA has had a significant part to play. Thus, Villaverde (2011) reviewed the emergence of nanoparticles in translational science and medicine and Banerjee et al. (2010) had focused on the role and biomedical applications that magnetic nanoparticles play in that nanomedicine. Similarly, the impact and biomedical applications of a different specific subset of nanoparticles, nanostructured carbiobeads, has also been reviewed (Stanishevsky et al., 2011).

Spotlight

The role that nanoparticles play in the rapidly developing field of ‘NanoMedicine’ has been discussed previously in Chapter 5. In this Chapter, we review the specificmechanisms by which such nanoparticles are designed and formulated and in which NTA has had a significant part to play. Thus, Villaverde (2011) reviewed the emergence of nanoparticles in translational science and medicine and Banerjee et al. (2010) had focused on the role and biomedical applications that magnetic nanoparticles play in that nanomedicine. Similarly, the impact and biomedical applications of a different specific subset of nanoparticles, nanostructured carbiobeads, has also been reviewed (Stanishevsky et al., 2011).

Related News

Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV

Moleculin Biotech, Inc | October 07, 2020

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV-2, antiviral activity has now been documented for HIV, Zika and Dengue Fever.

Read More

RESEARCH

Pfizer/Biontech Weren't Alone: Moderna Covid-19 Vaccine Data Aimed in Ema Cyberattack

Moderna | December 16, 2020

It would appear that Pfizer and BioNTech's COVID-19 immunization was not the sole objective of a new cyberattack at the European Medicines Agency. Moderna said Monday that reports from its pre-accommodation conversations with EMA about its shot, mRNA-1273, were "unlawfully gotten to" by programmers, refering to a warning from the organization. The assailants didn't get individual data about preliminary members, Moderna said. The organization's EMA accommodation did exclude any information recognizing people in the examination. Now, no extra insights concerning the cyberattack, for example, the size of the penetrate or the character of any suspects—are accessible, and Moderna said it anticipates results from EMA's progressing examination. The disclosure came days after the EMA initially uncovered the cyberattack, and Pfizer and BioNTech's COVID-19 immunization applicant, BNT162b2, was the principal distinguished as an objective. EMA choices on the two immunizations are moving close. Medication commentators at the EMA's Committee for Medicinal Products for Human Use are booked to evaluate BNT162b2 on Dec. 29 and mRNA-1273 on Jan. 12. Moderna was recently focused by programmers looking for its COVID-19 examination, in a cyberattack supposedly upheld by the Chinese government. The U.S. Branch of Justice in July arraigned two Chinese nationals for running a 10-year hacking effort that most as of late rotated to focusing on organizations doing COVID research. Reuters later affirmed Moderna as the antibody producer referenced in the arraignment. China has denied any function in such practices. Other than Moderna and Pfizer/BioNTech, rival COVID immunization designers AstraZeneca, Johnson and Johnson and Novavax apparently have arrived in the line of sight of North Korean programmers. In those hacking endeavors, the assailants regularly conveyed noxious reports or connections by means of email under the appearance of occupation enrollment specialists, partners or different associates of the person in question, as indicated by individuals acquainted with the issue refered to by The Wall Street Journal. Country state programmers from Iran and Russia have likewise been blamed for attempting to take COVID-related data.

Read More

PRACTICE MANAGEMENT

AvKARE bottles mix Viagra generics with antidepressant, triggering recall

AvKARE | December 15, 2020

A conventional drugmaker with a Rolodex loaded with government customers is pulling an energizer and an erectile brokenness medications after the two were bundled together in similar containers. Pulaski, Tennessee-based AvKARE reviewed one parcel of sildenafil 100-mg tablets and one parcel of trazodone 100-mg tablets after the items were stirred up by an outsider bundling provider, the organization said before the end of last week. The jugs had just been delivered to drug stores. AvKARE markets its own private-name conventional medications to a record of government customers, including the branches of Defense, Veterans Affairs and the Health and Human Services. The organization additionally supplies the Indian Health Services, in addition to nongovernment clients around the world. The customer level review influences parts sent to merchants and wholesalers and afterward delivered out from one side of the country to the other, the organization said. The sildenafil part has a March 2022 termination date, while the trazodone parcel lapses in June 2022. AvKARE said it so far hasn't got any result reports from the reviewed parcels. Sildenafil—a nonexclusive rendition of Viagra—can blend inadequately with nitrate-containing drugs for diabetes, hypertension or coronary illness, conceivably bringing pulse down to perilous levels. The upper trazodone hydrochloride, in the interim, can cause sluggishness, dazedness, stoppage and obscured vision, AvKARE cautioned. Those results represent a more serious danger of falls and impeded driving in more seasoned clients who may have bought the organization's erectile brokenness copycat.

Read More